TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02215954
Drug: Niflec
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
Study: NCT02714699
Drug: diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will take oral diclofenac potassium; two tablets (cataflam 25 mg) and one tablet placebo one hour before the procedure
Study: NCT02714699
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will take oral placebo; 2 tablets one hour before the procedure
Study: NCT02638623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional fluids will be administered
Study: NCT03198793
Drug: QGC001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]) over 8 weeks.
Study: NCT01657266
Drug: PRO-155
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-medication (before surgery) and maintenance treatment.
Study: NCT02322814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
Study: NCT03846414
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
Study: NCT00004390
Drug: desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02053519
Drug: Active Comparator: Vigantol Oil (Vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D Oral oil 100.000iu in 5 mls
Study: NCT02053519
Drug: Mygliol Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo comparator
Study: NCT01199159
Drug: Vitamin B 6
Normalized name: vitamin B 6 100 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
Study: NCT03253133
Drug: LV5FU or Folfiri
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of chemotherapy by LV5FU or Folfiri according pratician choice
Study: NCT02422186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
Study: NCT02005783
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide:600mg/m2, d1, q3w\*4
Study: NCT03448159
Drug: Fluoxetine Hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).
Study: NCT03455218
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass
Study: NCT03455218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: INOmax device connected to oxygenator, but no gas is delivered
Study: NCT03311932
Drug: Infacort®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release multiparticulate formulation (granules) of hydrocortisone
Study: NCT03311932
Drug: Cortef®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release hydrocortisone tablets
Study: NCT01334762
Drug: CC/IUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
Study: NCT00555204
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg - capsules once daily for 12 weeks
Study: NCT00555204
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg - capsules once daily for 12 weeks
Study: NCT00555204
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg - capsules once daily for 12 weeks
Study: NCT00555204
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg - capsules once daily for 12 weeks
Study: NCT00555204
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg - capsules once daily for 12 weeks
Study: NCT00555204
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg - capsules once daily for 12 weeks
Study: NCT00555204
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo - capsules once daily for 12 weeks
Study: NCT00799136
Drug: R-EPOCH and cART
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
Study: NCT03665753
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject will receive 10, 20, and 30mg of Ketorolac.
Study: NCT00002760
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
Study: NCT01871558
Drug: sulfonylurea (SU)
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04112641
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
Study: NCT04317001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01892891
Drug: VBY-036
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathepsin S inhibitor
Study: NCT03598725
Drug: Coagulation Factor VIII
Normalized name: Coagulation factor VIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
Study: NCT02629120
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post transplant cyclophosphamide given to prevent graft verses host disease. This is a well studied drug, and is not under an IND.
Study: NCT02707042
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day oral course of once-daily azithromycin
Study: NCT01627782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
Study: NCT02040558
Drug: MNK-010
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003640
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02281526
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00171873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride intramuscularly every 28 days
Study: NCT03092245
Drug: OctaplasLG
Approvals — FDA: no, EMA: no, PMDA: no
Description: OctaplasLG is given as an infusion when resuscitation fluids are required.
Study: NCT01120288
Drug: EZN-2968
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001721
Drug: Cholesterol Suspension
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00671398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally for one night only
Study: NCT00880308
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01897831
Drug: xin te mie
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
Study: NCT03235219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study: NCT00942981
Drug: PET
Normalized name: PETN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain dopamine D1 and D2/3 receptor regional binding potentials measured by \[11C\]NNC-112 and \[18F\]Fallypride PET.
Study: NCT03700450
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
Study: NCT02944656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
Study: NCT04376827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.
Study: NCT01804673
Drug: Fentanyl-ITS
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
Study: NCT03796026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
Study: NCT04036500
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given estradiol: 1 mg oral and 1 mg sublingual.
Study: NCT00082199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, Once daily, 12 weeks.
Study: NCT02277444
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate BSA-based dose (10 to 30 mg/m\^2 per week for participants with BSA \<1.67 m\^2, or minimum of 15 mg/week for participants with BSA \>=1.67 m\^2) weekly at least through Week 28.
Study: NCT03236987
Drug: Clarithromycin 1000 MG
Normalized name: clarithromycin 1000 MG
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
Study: NCT03236987
Drug: Azithromycin 250 mg
Normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
Study: NCT03301233
Drug: estradiol valerate and sildenafil
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
Study: NCT03922724
Drug: IOC
Normalized name: Biocef
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2
Study: NCT03992846
Drug: Placebo capsule to match Add-back capsule
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT03114371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.
Study: NCT03401268
Drug: subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
Study: NCT03993236
Drug: Experimental: Rosuvastatin/Ezetimibe 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Rosuvastatin/Ezetimibe 10/10mg~* orally administered once daily for 90 days
Study: NCT03993236
Drug: Active Comparator: Rosuvastatin 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Rosuvastatin 20mg~* orally administered once daily for 90 days
Study: NCT01493960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal dose at week 0 and 4
Study: NCT01742637
Drug: Epiduo® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
Study: NCT01742637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
Study: NCT04551196
Drug: Alternating Acetaminophen and Ibuprofen
Normalized name: acetaminophen / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.
Study: NCT04551196
Drug: Combined Acetaminophen and Ibuprofen
Normalized name: acetaminophen / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
Study: NCT00325546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00659594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02357290
Drug: Open-label Treatment with N-Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02254408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally or via nasogastric tube
Study: NCT00981474
Drug: blood pressure maintenance based on cerebral blood flow autoregulation measurement
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure lowered or raised
Study: NCT01401413
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control i pill nightly for 30 nights
Study: NCT00172120
Drug: ALX1-11
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03815084
Drug: pd-1 and DC-NK cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .
Study: NCT00487734
Drug: Placebo for testosterone gel
Normalized name: testosterone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel, 2.5g for each gel packet
Study: NCT01993017
Drug: Antidepressant Medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated.
Study: NCT01161472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
Study: NCT01619332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
Study: NCT01619332
Drug: LEZ763
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
Study: NCT03117725
Drug: Melatonin adminstration
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
Study: NCT00239070
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03117725
Drug: placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
Study: NCT04233502
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing
Study: NCT04233502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo melatonin
Study: NCT04353817
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet for oral administration qd in the morning.
Study: NCT01136213
Drug: Fluoxétine / Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
Study: NCT04430790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose and continuous placebo infusion.
Study: NCT00303160
Drug: vitamin C & E supplements
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02222961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02415777
Drug: Ursodeoxycholic acid, thiamine, riboflavin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00401635
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00603265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02299804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active ingredient
Study: NCT01207323
Drug: MEHD7945A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEHD7945A will be administered as specified in the individual arms.
Study: NCT01919996
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
Study: NCT00602680
Drug: SSR180711C
Approvals — FDA: no, EMA: no, PMDA: no
Description: duration of treatment: 4 weeks
Study: NCT00602680
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: duration of treatment: 4 weeks
Study: NCT03600896
Drug: CYT107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~* 5 mcg/kg/dose for 3 doses~* 10 mcg/kg/dose for 3 doses~* 20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II.
Study: NCT00953212
Drug: beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 25mg by mouth every 6 hours
Study: NCT00986362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravitreal injection
Study: NCT00953212
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
Study: NCT01299298
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
Study: NCT02965053
Drug: EOS789
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02965053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00172042
Drug: Zoledronic acid 4 mg
Normalized name: zoledronic acid 4 MG
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
Study: NCT04189640
Drug: Postoperative analgesia management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.